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tier drug beneﬁt plan at a managed care plan in Toledo-
Ohio, were reviewed retrospectively. The top ten therapy
classes based on net costs to the health plan were selected
for analysis. The records for these classes were extracted
using the Rx Clients Report v 5.0 software at the health
plan. Data were analyzed using Microsoft Excel 2000.
RESULTS: On average 1) PMPM ingredient costs
increased 16.5% for the preferred drugs and decreased
7.4% for the non-preferred drugs; 2) PMPM utilization
increased 19.3% for the preferred drugs and decreased
12.7% for the non–preferred drugs and; 3) Ingredient
cost per prescription increased 2.8% for the preferred
drugs and also increased 4.7% for the non-preferred
drugs. The increase in the PMPM ingredient costs and
PMPM utilization maybe due to the utilization of the
most expensive preferred drugs on the formulary. The
ingredient costs per prescription were not skewed either
towards the preferred or the non-preferred drugs.
CONCLUSION: The implementation of a three-tier drug
co-payment caused a decrease in the PMPM ingredient
costs and PMPM utilization of the non-preferred drugs.
It generated cost-savings to the managed care plan over
a period of two years by shifting the members from 
high cost non-preferred drugs to the lower cost preferred
drugs.
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Economic evaluation of medical technologies in Japan is
challenging because of a lack of data sources.
OBJECTIVE: This paper reviews the data sources avail-
able for conducting pharmacoeconomics research in
Japan, and discusses health policy reforms that may
increase the demand for pharmacoeconomics studies in
the future.
METHODS: A literature review of pharmacoeconomic
studies was conducted in both English (MEDLINE 
OHE-HEED) and Japanese publications (JAPICDOC) to
identify the typical data sources used in these studies.
Reﬂecting on ﬁrst hand experience conducting outcomes
research in Japan, we summarized (percent of studies 
utilizing the different data source types) and commented
on the data sources.
RESULTS: A total of 42 published studies were found 
in the Japanese and English literature from 1980–2001.
Typical sources identiﬁed for resource utilization data
included: clinical trials (62%), epidemiology/case studies
(43%), patient chart reviews (52%), expert panels (12%).
Sources for clinical efﬁcacy or disease state transition
probabilities included: clinical trials (60%), epidemiol-
ogy/case studies (36%), patient chart reviews (29%),
expert panels (12%). The cost data sources identiﬁed
were: 1) national uniform reimbursement fees (98%)—
Japanese Ministry of Health, Labor and Welfare
(MHLW), 2) micro-cost studies (2%). The MHLW
uniform fees represent costs from the health insurance
plan viewpoint, and therefore are relevant in drug price
negotiations with the MHLW. Demand for pharma-
coeconomic data may increase because of: 1) upcoming
MHLW pharmaceutical pricing and/or health insurance
system reforms; 2) new regulatory committees e.g. NICE.
CONCLUSION: Access to data sources for pharma-
coeconomic research is generally known to be limited 
in Japan, however several published studies effectively
overcame such limitations. Compared to other countries,
however, detailed population-based data are still rela-
tively unavailable. Upcoming health care reforms may
increase the demand for pharmacoeconomic data in
Japan, thus, increasing the demand for better sources of
data typically needed for these studies.
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OBJECTIVE: Although there are nearly a quarter of a
million hospitalizations for traumatic brain injury (TBI)
in the U.S. each year, economic data on TBI treatment are
limited. The purpose of this study was to estimate the out-
comes and costs of acute inpatient treatment of TBI.
METHODS: Using a large, geographically-diverse, multi-
hospital database, we examined inpatient records for
persons aged 16 years or older who were hospitalized for
TBI between January 1, 1997 and June 30, 1999. Patients
were stratiﬁed by TBI severity using an adaptation of 
the Abbreviated Injury Scale for administrative data
(ICD/AIS), as follows: 2, “moderate”; 3, “serious”; 4,
“severe”; and 5, “critical”. Patient characteristics, pat-
terns of treatment, and outcomes and costs were exam-
ined by injury severity and mechanism of injury. Costs of
treatment were estimated from billed charges using cost-
to-charge ratios from the Medicare Prospective Payment
System.
RESULTS: Of 8,717 study subjects identiﬁed, 12.5% had
moderate, 44.8% serious, 29.6% severe, and 13.2% 
critical TBI. Falls were the most common reported cause
of injury (40.8%), followed by motor-vehicle accidents
(39.3%), blows to the head (11.3%), and gunshot
wounds (2.4%). Average length of stay in hospital ranged
from 6.7 days for moderate TBI to 17.5 days for critical
TBI. The overall rate of death in hospital was relatively
low among patients with moderate (1.3%), serious
(5.7%), and severe (8.7%) TBIs, but much higher among
the most critically injured patients (52.0%). Costs of hos-
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pitalization averaged $8,189 for moderate, $14,603 for
serious, $16,788 for severe, and $33,537 for critical TBI.
Costs also varied by injury type, averaging $20,084 for
gunshot wounds, $20,522 for motor-vehicle accidents,
$15,860 for falls, and $19,949 for blows to the head.
CONCLUSIONS: The economic burden of TBI in the
acute-care setting is substantial; treatment outcomes and
costs vary considerably by TBI severity and mechanism
of injury.
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Pharmaceutical care is known to help improve patient
quality of life, reduce adverse events and help reduce
healthcare costs.
OBJECTIVES: This paper aims to identify the current
level of cognitive pharmacy services that patients receive
in ambulatory pharmacy settings and the amount patients
are willing-to-pay for these services.
METHODS: A self-administered questionnaire was 
constructed and tested for validity. The questionnaire 
was distributed at two randomly selected ambulatory 
care pharmacies in Maryland. The instrument asked 
questions regarding demographics, current level of cog-
nitive pharmacy services the patient was receiving and 
the dollar amount the patient was willing-to-pay for the
service.
RESULTS: 91 people responded. Thirty-one percent of
the respondents were between the ages of 45 and 65 and
approximately 13% of the respondents were Hispanic.
The majority of the respondents were female (60%) and
about 33% had completed trade school or college. The
major insurance type was HMO/Medicare (41.8%) and
about 31.2% of respondents reported an annual income
between $20–30K. Sixty-three percent of respondents
reported a household size of two to four persons. Almost
80% of respondents reported their perceived health status
to be good/very good. Almost one-half (48.4%) of
respondents reported never receiving any detailed coun-
seling about their medications, and 60% of respondents
reported never receiving any monitoring services. The
respondents were willing-to-pay $0–10 (58.2%) and
$11–20 (29.7%) for a single pharmaceutical care evalu-
ation. The respondents were willing-to-pay $41–50
(16.5%) for a pharmaceutical care evaluation with a year
of monitoring by the pharmacist. Although, 36.3% of 
the respondents were only willing-to-pay between $0–10.
The majority of respondents reported that insurance 
companies should cover cognitive pharmacy services.
CONCLUSIONS: The results suggest that the majority of
the respondents are not receiving cognitive pharmacy ser-
vices; although, many of them would be willing-to-pay
for this type of service.
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OBJECTIVES: While pharmacoeconomic research is
often used as a tool to assist decision on product reim-
bursement, Budget Impact Analysis (BIA) is increasingly
required by decision-makers to ascertain the macro-
economic consequences of new product reimbursement 
in addition to proof of cost-effectiveness. BIA provides
insight into ﬁnancial consequences of reimbursing a new
technology. Poland is in the process of drafting country-
speciﬁc guidelines for BIA, positioned as complementary
to economic evaluation in decision making. The aim of
this study is to compare project of Polish BIA guidelines
with existing international guidance, highlighting areas of
agreement and dissent.
METHODS: Guidelines from ﬁve countries (Australia,
Canada, Netherlands, England & Wales, France, USA)
were reviewed, analyzed and comparison was under-
taken. The following areas were analysed: objective, 
use of BIA, responsibility in their conduct, target audi-
ence, methodology and ethical code of practice while 
conducting and in the publication of results. An analysis
of the differences between different national guide-
lines and their Polish counterparts was subsequently
undertaken.
RESULTS: Current international guidance for BIA is
limited, often unclear and variable in terms of deﬁning
what constitutes BIA and how it should be undertaken.
Australian PBAC guidelines for economic evaluation
provide most detail into how BIA should be undertaken
and reported. In comparison to existing guidance 
project of Polish BIA guidelines appears to be more
detailed and includes recommendations on perspective,
time horizon, reliability of data sources, reporting of
results, rates of adoption of new therapies, probability of
re-deploying resources. The intention was to establish
principles for best practice in designing and implement-
ing BIA.
CONCLUSIONS: Whilst there is an increased demand
for BIA, there is only limited guidance on how such
studies should be undertaken. It is hoped, that the Polish
guidelines can contribute to the development of such
analyses and deliver beneﬁt for Polish healthcare decision
makers and beyond.
